The global cancer stem cells market size reached USD 1.91 billion in 2023 and is estimated to hit around USD 6 billion by 2033 with a CAGR of 12.14% from 2024 to 2033. The rising prevalence of cancer cases all around the world and the rising investment in the development of cancer treatment are driving the growth of the cancer stem cells market.
To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics
The U.S. cancer stem cells market size reached USD 590 million in 2023 and is anticipated to reach around USD 1,850 million by 2033, poised to grow at a CAGR of 12.20% from 2024 to 2033.
North America led the global market with the highest market share of 44% in 2023. The growth of the market in the region is increasing due to the well-established healthcare sector and developed economies like the United States and Canada investing in the development of treatment and medication for various chronic diseases. The increasing presence of the major pharmaceutical companies and research centers is also boosting the growth of the market.
The technologically advanced healthcare infrastructure and the biomedical research centers are proactively researching numerous types of cancer treatment for effective results and innovations. All these factors are collectively contributing to the growth of the cancer stem cells market across the region.
Asia Pacific is expected to witness the fastest rate of expansion in the market during the forecast period. The growth of the market in the region is expected to be boosted due to the rising population and the increasing number of cancer cases in women, the geriatric population, etc.
The growing penetration of cancer cases is resulting in a higher demand for efficient and effective treatment, leading to a higher demand for the market. Furthermore, rising investments in research and development activities and government initiatives for battling against the rising cancer cases are driving the growth of the cancer stem cells market across the region.
Cancer stem cells are the major factor responsible for the development of cancer tumors. It is the subpopulation of the cells found in the tumorigenic tumor. Cancer stem cells have properties like self-renewal and differentiation into various cell types. It produces or regenerates itself in the human body and sustains cancer in the body. It is responsible for the growth and metastasis of cancer.
There are different types of cancer are identified in the human body, such as breast, brain, colon, pancreatic, ovarian, and prostate tumors. In stem cell therapy, stem cells are given to cancer-affected people to replace cells that have been destroyed or eliminated. In cancer-affected people, it is used for regaining the body’s ability to produce stem cells after the treatment. The increasing prevalence of cancer cases due to the changing lifestyle, urbanization, and habits are driving the growth of the cancer stem cells market.
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 12.14% |
| Global Market Size in 2023 | USD 1.91 Billion |
| Global Market Size by 2033 | USD 6 Billion |
| U.S. Market Size in 2023 | USD 590 Million |
| U.S. Market Size by 2033 | USD 1,850 Million |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type and By Applications |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver: The rising prevalence of cancer cases
The global surge in cancer cases due to the various regions driving the efficient treatment of the disease is driving the demand for the market. The cancer stem cells are one of the most important parts of the treatment of cancer in the initial state. Cancer stem cell therapy targets specific cancer cells and aims to eliminate the chances of cancer coming post-chemotherapy, surgery, or radiation therapy. Cancer stem cell therapy has intricate processes like genetic modulation, cell isolation, and personalized treatment planning. Thus, all these factors collectively contribute to the growth of the cancer stem cells market.
Restraint: Higher cost
The development of cancer stem cell therapy requires extensive research, clinical trials, and preclinical investigations, which requires a significant amount of time and financial investment, which results in a higher cost of the treatment. The increased expenditure during the clinical and preclinical phases directly corresponds to a higher retail price of the drug on approval. The high price associated with cancer treatment restrains the growth of the cancer stem cells market.
Opportunity: Increasing investment and research and development activities
The rising cases of cancer lead to a higher demand for research-based activities in the sector. The increasing demand for treatment and medication due to the increasing types of cancer cases, such as leukemia, lymphoma, and osteopetrosis, are driving the demand for cancer stem cell therapy for the treatment. The extensive research and development activities for the development of cancer treatment and medications and the rising investments by the major pharmaceutical industry and the government bodies for the development of research centers and reducing the number of cancer diseases are collectively contributing to the growth of the cancer stem cells market.
The breast cancer segment dominated the cancer stem cells market in 2023. The growth of the segment is attributed to the changing lifestyle preferences of women, which are driving the growth of the segment in the market. Breast cancer is the most commonly seen cancer in women due to various factors such as genetics, excessive fat consumption, exposure to chemicals, alcohol consumption, increasing age, mammographic density, reproductive variables, etc. are some of the considered potential risks for breast cancer in women.
Increasing urbanization and industrialization, changing diets, and reduced physical activities are all contributing to the growth of breast cancer in women. Breast cancer stem cells could be targeted via immunotherapy like adoptive T-cell transfer or dendritic cell (DC)-based therapies which are used in the treatment regimes.
During the forecast period, the bladder cancer segment is expected to increase its growth in the cancer stem cells market. The growth of the segment is attributed to the rising number of bladder cancer cases worldwide, and it is considered the ninth most common disease in the world. The bladder cancer is a malignant development of the aberrant cells. Smoking is the major cause of bladder cancer. It is the most prevalent genitourinary cancer, which is responsible for causing 150,000 deaths every year. There are different treatments for bladder cancer, including open surgery, endoscopic, chemotherapy, immunotherapy, and radiotherapy, which are used for the treatment of this cancer.
The stem cell-based cancer therapy segment dominated the cancer stem cells market in 2023. The growth of the segment is attributed to the higher effectiveness of the treatment as compared to the other procedures that are driving the growth of the cancer stem cells market. Traditional therapies such as chemotherapeutics cannot eliminate the metastatic cancer cells, and there is a higher chance of recurrence of cancer cells. Stem-cell cancer therapy is gaining popularity as the most promising treatment for cancer and eliminating cancer cells.
The therapy is used as a nanoparticle and viral carrier for enhancing the primary therapeutics and reducing the side effects of the treatment. Stem cell therapy is the most effective cancer treatment procedure with unique biological actions, including directional migration, self-renewal, differentiation, and effects on the other cells, which are used as generative medicines, drug targeting, therapeutics carriers, and generation of immune cells.
The targeted cancerous stem-cell cancer therapy segment is expected to grow at a significant rate in the cancer stem cells market during the projected period. Cancer stem cells are the major cause of the recurrence of cancer cells and metastasis. Recent advancements in immunotherapies have shown some promising results in cancer treatment that apply to target cancer stem cells. The cancer stem cells express the immune markers and limit the distinctive immune properties that can be implemented in immunotherapies to target cancer stem cells of the tumor microenvironment.
Segments Covered in the Report
By Type
By Applications
By Geography
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
